GlassScriptPhysician profile
Amanda D Moroz
NPI 1043832520
$3,806.44
in general payments reported to CMS, 2019-2025
22 companies · $891 in 2025
The $891 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $279 · 2022: $458 · 2023: $854 · 2024: $1,325 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,069.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,112.07 | 2021-2025 | |
| Alkermes, INC. | $457.06 | 2021-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $424.32 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $298.54 | 2021-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $216.38 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $183.91 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $150.58 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $129.23 | 2024-2025 | Auvelity, Sunosi |
| Corium, LLC | $127.26 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $117.71 | 2021-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $95.44 | 2023-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $86.01 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $79.21 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $59.68 | 2023-2025 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $47.86 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $46.14 | 2022-2024 | Quviviq |
| Neos Therapeutics, LP | $43.94 | 2021-2023 | Adzenys Xr-Odt |
| Tris Pharma INC | $43.11 | 2022-2023 | Dyanavel Xr |
| Indivior INC. | $32.21 | 2024 | Perseris |
| Vanda Pharmaceuticals INC. | $29.08 | 2021-2025 | Fanapt |
| Bausch Health US, LLC | $13.58 | 2024 | Aplenzin |
| Adlon Therapeutics L.P. | $13.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Moroz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.